Advancements in cancer detection and liquid biopsy

Medical research has focused on advancing liquid biopsy and microfluidic technologies for cancer detection and monitoring.

Initial developments included a 3D-printed portable microfluidic device created by researchers at MIT and Johns Hopkins University to collect live cells from specific tissues, such as Fallopian tubes, to study early-stage ovarian cancer behavior. Concurrently, the NHS-Galleri trial in the United Kingdom evaluated a multi-cancer blood test analyzing epigenetic methylation signals; however, secondary analyses raised questions regarding false positives and clinical utility.

Subsequent research expanded on these methods through specialized assays and AI integration. A study at Houston Methodist Hospital utilized a personalized, tumor-informed ctDNA assay to detect cancer recurrence in liver transplant patients, achieving high sensitivity when combined with standard biomarkers. Additionally, researchers from Taiyuan University of Technology and Shanxi Bethune Hospital developed a label-free microfluidic chip that employs deep learning to identify circulating tumor cells from bright-field images without requiring specific cell-surface markers.